Delft reports rise in medical orders:
This article was originally published in Clinica
Dutch instruments manufacturer Delft has reported that its order intake in the medical sector rose substantially in the first half, mainly due to demand for radiotherapy and diagnostics products. In this period revenues declined 5% to Fl 188.2 million ($113 million). Delft blames the lower sales on a disposal, but also says that sales in the medical sector were slightly lower. Net profit rose to Fl 3.1 million compared with Fl 1.5 million last year.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.